Which has stronger valuation and earnings, SLDB or NERV?

Solid Biosciences is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Solid Biosciences N/A N/A -$174.32M -$1.95 N/A Minerva Neurosciences N/A N/A -$293.42M -$29.16 N/A

Is SLDB or NERV more profitable?

Minerva Neurosciences' return on equity of 0.00% beat Solid Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Solid Biosciences N/A -73.42% -61.13% Minerva Neurosciences N/A N/A -32.63%

Does the media prefer SLDB or NERV?

In the previous week, Solid Biosciences had 2 more articles in the media than Minerva Neurosciences. MarketBeat recorded 4 mentions for Solid Biosciences and 2 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 1.75 beat Solid Biosciences' score of 1.28 indicating that Minerva Neurosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solid Biosciences 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Minerva Neurosciences 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to NERV or CYRX?

In the previous week, CryoPort had 1 more articles in the media than Minerva Neurosciences. MarketBeat recorded 3 mentions for CryoPort and 2 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 1.75 beat CryoPort's score of 0.60 indicating that Minerva Neurosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Minerva Neurosciences 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive CryoPort 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ACRS or NERV?

In the previous week, Aclaris Therapeutics had 1 more articles in the media than Minerva Neurosciences. MarketBeat recorded 3 mentions for Aclaris Therapeutics and 2 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 1.75 beat Aclaris Therapeutics' score of 1.24 indicating that Minerva Neurosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aclaris Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Minerva Neurosciences 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has stronger valuation & earnings, NERV or DSGN?

Design Therapeutics is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Minerva Neurosciences N/A N/A -$293.42M -$29.16 N/A Design Therapeutics N/A N/A -$69.79M -$1.20 N/A

Is NERV or DSGN more profitable?

Minerva Neurosciences' return on equity of 0.00% beat Design Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Minerva Neurosciences N/A N/A -32.63% Design Therapeutics N/A -33.07% -31.29%

Does the media favor NERV or DSGN?

In the previous week, Design Therapeutics had 3 more articles in the media than Minerva Neurosciences. MarketBeat recorded 5 mentions for Design Therapeutics and 2 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 1.75 beat Design Therapeutics' score of 0.39 indicating that Minerva Neurosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Minerva Neurosciences 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Design Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, AURA or NERV?

Aura Biosciences is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aura Biosciences N/A N/A -$106.19M -$1.74 N/A Minerva Neurosciences N/A N/A -$293.42M -$29.16 N/A

Is AURA or NERV more profitable?

Minerva Neurosciences' return on equity of 0.00% beat Aura Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Aura Biosciences N/A -78.12% -64.08% Minerva Neurosciences N/A N/A -32.63%

Minerva Neurosciences (NERV) Competitors

$3.97 -0.01 (-0.25%)

Closing price 04:00 PM Eastern

Extended Trading

$3.96 -0.01 (-0.13%)

As of 04:19 PM Eastern

Compare

NERV vs. SLDB, CYRX, ACRS, DSGN, and AURA

Should you buy Minerva Neurosciences stock or one of its competitors? MarketBeat compares Minerva Neurosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Minerva Neurosciences include Solid Biosciences (SLDB), CryoPort (CYRX), Aclaris Therapeutics (ACRS), Design Therapeutics (DSGN), and Aura Biosciences (AURA).

How does Minerva Neurosciences compare to Solid Biosciences?

Solid Biosciences (NASDAQ:SLDB) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

Solid Biosciences is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$1.95	N/A
Minerva Neurosciences	N/A	N/A	-$293.42M	-$29.16	N/A

Solid Biosciences presently has a consensus price target of $17.11, indicating a potential upside of 113.36%. Minerva Neurosciences has a consensus price target of $10.50, indicating a potential upside of 164.48%. Given Minerva Neurosciences' higher possible upside, analysts plainly believe Minerva Neurosciences is more favorable than Solid Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
Minerva Neurosciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Solid Biosciences has a beta of 2.41, indicating that its share price is 141% more volatile than the broader market. Comparatively, Minerva Neurosciences has a beta of -0.1, indicating that its share price is 110% less volatile than the broader market.

Minerva Neurosciences' return on equity of 0.00% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-73.42%	-61.13%
Minerva Neurosciences	N/A	N/A	-32.63%

81.5% of Solid Biosciences shares are owned by institutional investors. Comparatively, 34.6% of Minerva Neurosciences shares are owned by institutional investors. 2.7% of Solid Biosciences shares are owned by insiders. Comparatively, 1.7% of Minerva Neurosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Solid Biosciences had 2 more articles in the media than Minerva Neurosciences. MarketBeat recorded 4 mentions for Solid Biosciences and 2 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 1.75 beat Solid Biosciences' score of 1.28 indicating that Minerva Neurosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solid Biosciences	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Minerva Neurosciences	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Solid Biosciences beats Minerva Neurosciences on 9 of the 14 factors compared between the two stocks.

How does Minerva Neurosciences compare to CryoPort?

Minerva Neurosciences (NASDAQ:NERV) and CryoPort (NASDAQ:CYRX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations and risk.

In the previous week, CryoPort had 1 more articles in the media than Minerva Neurosciences. MarketBeat recorded 3 mentions for CryoPort and 2 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 1.75 beat CryoPort's score of 0.60 indicating that Minerva Neurosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Minerva Neurosciences	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
CryoPort	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

34.6% of Minerva Neurosciences shares are held by institutional investors. Comparatively, 92.9% of CryoPort shares are held by institutional investors. 1.7% of Minerva Neurosciences shares are held by company insiders. Comparatively, 9.5% of CryoPort shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Minerva Neurosciences has a beta of -0.1, meaning that its share price is 110% less volatile than the broader market. Comparatively, CryoPort has a beta of 1.89, meaning that its share price is 89% more volatile than the broader market.

CryoPort has a net margin of 41.57% compared to Minerva Neurosciences' net margin of 0.00%. Minerva Neurosciences' return on equity of 0.00% beat CryoPort's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Minerva Neurosciences	N/A	N/A	-32.63%
CryoPort	41.57%	-7.92%	-4.79%

Minerva Neurosciences presently has a consensus price target of $10.50, indicating a potential upside of 164.48%. CryoPort has a consensus price target of $16.38, indicating a potential upside of 5.71%. Given Minerva Neurosciences' higher possible upside, equities analysts plainly believe Minerva Neurosciences is more favorable than CryoPort.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Minerva Neurosciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
CryoPort	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78

CryoPort has higher revenue and earnings than Minerva Neurosciences. Minerva Neurosciences is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Minerva Neurosciences	N/A	N/A	-$293.42M	-$29.16	N/A
CryoPort	$176.18M	4.43	$78.30M	$1.35	11.47

Summary

CryoPort beats Minerva Neurosciences on 12 of the 15 factors compared between the two stocks.

How does Minerva Neurosciences compare to Aclaris Therapeutics?

Aclaris Therapeutics (NASDAQ:ACRS) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, profitability, analyst recommendations, risk and valuation.

98.3% of Aclaris Therapeutics shares are owned by institutional investors. Comparatively, 34.6% of Minerva Neurosciences shares are owned by institutional investors. 4.8% of Aclaris Therapeutics shares are owned by insiders. Comparatively, 1.7% of Minerva Neurosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Aclaris Therapeutics had 1 more articles in the media than Minerva Neurosciences. MarketBeat recorded 3 mentions for Aclaris Therapeutics and 2 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 1.75 beat Aclaris Therapeutics' score of 1.24 indicating that Minerva Neurosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aclaris Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Minerva Neurosciences	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Aclaris Therapeutics currently has a consensus price target of $11.50, indicating a potential upside of 107.96%. Minerva Neurosciences has a consensus price target of $10.50, indicating a potential upside of 164.48%. Given Minerva Neurosciences' higher probable upside, analysts clearly believe Minerva Neurosciences is more favorable than Aclaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13
Minerva Neurosciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Aclaris Therapeutics has higher revenue and earnings than Minerva Neurosciences. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclaris Therapeutics	$7.83M	98.64	-$64.92M	-$0.56	N/A
Minerva Neurosciences	N/A	N/A	-$293.42M	-$29.16	N/A

Aclaris Therapeutics has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market. Comparatively, Minerva Neurosciences has a beta of -0.1, suggesting that its share price is 110% less volatile than the broader market.

Minerva Neurosciences has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -832.58%. Minerva Neurosciences' return on equity of 0.00% beat Aclaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclaris Therapeutics	-832.58%	-55.89%	-38.49%
Minerva Neurosciences	N/A	N/A	-32.63%

Summary

Aclaris Therapeutics beats Minerva Neurosciences on 10 of the 16 factors compared between the two stocks.

How does Minerva Neurosciences compare to Design Therapeutics?

Minerva Neurosciences (NASDAQ:NERV) and Design Therapeutics (NASDAQ:DSGN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.

Minerva Neurosciences currently has a consensus price target of $10.50, indicating a potential upside of 164.48%. Design Therapeutics has a consensus price target of $16.50, indicating a potential upside of 29.31%. Given Minerva Neurosciences' higher probable upside, equities analysts plainly believe Minerva Neurosciences is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Minerva Neurosciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

34.6% of Minerva Neurosciences shares are held by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are held by institutional investors. 1.7% of Minerva Neurosciences shares are held by insiders. Comparatively, 17.1% of Design Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Minerva Neurosciences' return on equity of 0.00% beat Design Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Minerva Neurosciences	N/A	N/A	-32.63%
Design Therapeutics	N/A	-33.07%	-31.29%

Minerva Neurosciences has a beta of -0.1, indicating that its share price is 110% less volatile than the broader market. Comparatively, Design Therapeutics has a beta of 1.63, indicating that its share price is 63% more volatile than the broader market.

Design Therapeutics is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Minerva Neurosciences	N/A	N/A	-$293.42M	-$29.16	N/A
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A

In the previous week, Design Therapeutics had 3 more articles in the media than Minerva Neurosciences. MarketBeat recorded 5 mentions for Design Therapeutics and 2 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 1.75 beat Design Therapeutics' score of 0.39 indicating that Minerva Neurosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Minerva Neurosciences	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Design Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Design Therapeutics beats Minerva Neurosciences on 10 of the 14 factors compared between the two stocks.

How does Minerva Neurosciences compare to Aura Biosciences?

Aura Biosciences (NASDAQ:AURA) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

In the previous week, Minerva Neurosciences had 2 more articles in the media than Aura Biosciences. MarketBeat recorded 2 mentions for Minerva Neurosciences and 0 mentions for Aura Biosciences. Minerva Neurosciences' average media sentiment score of 1.75 beat Aura Biosciences' score of 0.00 indicating that Minerva Neurosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Aura Biosciences	Neutral
Minerva Neurosciences	Very Positive

Minerva Neurosciences' return on equity of 0.00% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aura Biosciences	N/A	-78.12%	-64.08%
Minerva Neurosciences	N/A	N/A	-32.63%

Aura Biosciences is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A
Minerva Neurosciences	N/A	N/A	-$293.42M	-$29.16	N/A

96.8% of Aura Biosciences shares are owned by institutional investors. Comparatively, 34.6% of Minerva Neurosciences shares are owned by institutional investors. 1.9% of Aura Biosciences shares are owned by company insiders. Comparatively, 1.7% of Minerva Neurosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Aura Biosciences presently has a consensus target price of $20.50, indicating a potential upside of 191.19%. Minerva Neurosciences has a consensus target price of $10.50, indicating a potential upside of 164.48%. Given Aura Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Aura Biosciences is more favorable than Minerva Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Minerva Neurosciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Aura Biosciences has a beta of 0.4, suggesting that its stock price is 60% less volatile than the broader market. Comparatively, Minerva Neurosciences has a beta of -0.1, suggesting that its stock price is 110% less volatile than the broader market.

Summary

Aura Biosciences beats Minerva Neurosciences on 8 of the 13 factors compared between the two stocks.

Get Minerva Neurosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NERV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NERV vs. The Competition

Export

Metric	Minerva Neurosciences	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$185.42M	$11.63B	$6.86B	$12.45B
Dividend Yield	N/A	2.73%	2.60%	10.03%
P/E Ratio	-0.14	669.38	223.77	22.69
Price / Sales	N/A	731.49	588.10	92.16
Price / Cash	N/A	14.82	28.64	34.82
Price / Book	-1.22	10.39	11.02	6.21
Net Income	-$293.42M	$2.80B	$3.48B	$347.49M
7 Day Performance	-5.48%	0.30%	0.56%	0.89%
1 Month Performance	-22.16%	-3.70%	-4.14%	-3.60%
1 Year Performance	106.23%	156.59%	63.23%	20.46%

Minerva Neurosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NERV Minerva Neurosciences	1.7212 of 5 stars	$3.97 -0.3%	$10.50 +164.5%	+106.8%	$185.42M	N/A	N/A	9	News Coverage Positive News
SLDB Solid Biosciences	2.5098 of 5 stars	$7.97 +1.0%	$17.11 +114.7%	+18.0%	$776.77M	N/A	N/A	100	Positive News
CYRX CryoPort	2.4344 of 5 stars	$15.17 +0.1%	$16.38 +7.9%	+107.6%	$763.59M	$176.18M	11.24	1,186	Upcoming Earnings
ACRS Aclaris Therapeutics	2.4223 of 5 stars	$5.33 -0.7%	$11.50 +115.8%	+239.9%	$749.99M	$7.83M	N/A	100	Positive News Upcoming Earnings
DSGN Design Therapeutics	2.223 of 5 stars	$11.87 -0.1%	$16.50 +39.0%	+218.8%	$741.99M	N/A	N/A	40	News Coverage Positive News Earnings Report Upcoming Earnings Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NERV) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Minerva Neurosciences (NERV) Competitors

NERV vs. SLDB, CYRX, ACRS, DSGN, and AURA

How does Minerva Neurosciences compare to Solid Biosciences?

Summary

How does Minerva Neurosciences compare to CryoPort?

Summary

How does Minerva Neurosciences compare to Aclaris Therapeutics?

Summary

How does Minerva Neurosciences compare to Design Therapeutics?

Summary

How does Minerva Neurosciences compare to Aura Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NERV vs. The Competition

Minerva Neurosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Minerva Neurosciences (NERV) Competitors

NERV vs. SLDB, CYRX, ACRS, DSGN, and AURA

How does Minerva Neurosciences compare to Solid Biosciences?

Which has stronger valuation and earnings, SLDB or NERV?

Do analysts prefer SLDB or NERV?

Which has more volatility and risk, SLDB or NERV?

Is SLDB or NERV more profitable?

Do insiders and institutionals have more ownership in SLDB or NERV?

Does the media prefer SLDB or NERV?

Summary

How does Minerva Neurosciences compare to CryoPort?

Does the media refer more to NERV or CYRX?

Do insiders & institutionals believe in NERV or CYRX?

Which has more volatility & risk, NERV or CYRX?

Is NERV or CYRX more profitable?

Do analysts prefer NERV or CYRX?

Which has preferable valuation and earnings, NERV or CYRX?

Summary

How does Minerva Neurosciences compare to Aclaris Therapeutics?

Do insiders and institutionals have more ownership in ACRS or NERV?

Does the media prefer ACRS or NERV?

Do analysts recommend ACRS or NERV?

Which has better valuation and earnings, ACRS or NERV?

Which has more risk & volatility, ACRS or NERV?

Is ACRS or NERV more profitable?

Summary

How does Minerva Neurosciences compare to Design Therapeutics?

Do analysts rate NERV or DSGN?

Do insiders & institutionals believe in NERV or DSGN?

Is NERV or DSGN more profitable?

Which has more risk & volatility, NERV or DSGN?

Which has stronger valuation & earnings, NERV or DSGN?

Does the media favor NERV or DSGN?

Summary

How does Minerva Neurosciences compare to Aura Biosciences?

Does the media prefer AURA or NERV?

Is AURA or NERV more profitable?

Which has preferable valuation & earnings, AURA or NERV?

Do institutionals and insiders have more ownership in AURA or NERV?

Do analysts recommend AURA or NERV?

Which has more volatility and risk, AURA or NERV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NERV vs. The Competition

Minerva Neurosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools